PercayAI and Saint Louis University Partner to Accelerate AI Adoption in Biomedical Research

EQ IQ In order to offer transparency into how our stories are produced and to teach our readers about the importance of media literacy online, EQ's editorial team provides a quick self-rating of the integrity of the articles and the facts presented against the following EQ IQ metrics.
  • Directly Sourced
  • Edited by EQ

PercayAIโ€™s software helps researchers discover and develop more effective medicines faster than traditional methods.

St. Louis biotech startup PercayAI and Saint Louis University (SLU) have announced a partnership to provide SLU researchers with access to PercayAIโ€™s augmented intelligence (AI) drug discovery platform.

Using a unique combination of contextual language processing, novel heuristics, and machine learning, the software finds non-obvious contextual signals to help scientists rapidly understand the complete biological process relevant to their research – in days rather than months. Through the collaboration, PercayAI computational biologists and machine learning engineers will work closely with SLU faculty and students to train them on the use of PercayAIโ€™s AI platform and help them apply it to their current research projects.

โ€œThe early results from our collaboration with PercayAI are very encouraging,” said Fran Sverdrup, Ph.D., associate professor of biochemistry and molecular biology at SLU. “With the help of their AI platform, we were able to uncover new relationships in our data sets that led to new potential drug targets. We are excited to follow-up on these new leads and expand the use of their technology to help advance our drug discovery efforts in the rare disease space.โ€

One of the primary components of the PercayAI platform is CompBio, software co-developed with the Genome Technology Access Center at the McDonnell Genome Institute ([email protected]) at Washington University School of Medicine in St. Louis.

โ€œWith this software, researchers can organize and prioritize relevant data in ways that arenโ€™t possible with traditional methods, improving the speed, cost and success rate of drug research and development,โ€ said Preston Keller, Chief Commercial Officer at PercayAI. โ€œWeโ€™re excited to establish a close partnership with Saint Louis University and work with them to support and expand the biological research community in Saint Louis.โ€

Mentioned in this Article

blank
Stories published by EQ Staff indicate that the article is based on a press release that's been sent to the editorial team via EQ's submit a press release for consideration form. Check the EQ IQ score on every article to determine how much due diligence took place. Press release submissions are not guaranteed placements and are selected for publishing on a merit basis. Feel free to drop us a line to learn more or if you have any questions.

Recent Posts

Pluton Biosciences and Bayer AG to Investigate Microbial-Based Carbon Capture

Pluton Biosciences Accepted into Plug and Play AgTech Accelerator

Popular Posts

STL-based Immunophotonics is Taking on Cancer Using Your Own Body

Trends in Life Science and Healthcare Innovation

International Affair

Galera Therapeutics Raises $150 Million to Advance “Breakthrough Therapy” for Debilitating Cancer Side Effect